In a recent letter to the editor,1 Joel Lexchin discusses the results of his requests for published clinical information from 12 Canadian pharmaceutical companies. Pfizer Canada Inc. received a written request from Lexchin for a list of all randomized, controlled, fully published clinical trials regarding the use of sildenafil for treatment of erectile dysfunction published in English at the time the product was first marketed in Canada. On Sept. 24, 2001, we provided Lexchin with a list of the requested sildenafil studies. We were therefore surprised not to be mentioned by Lexchin as one of the companies who provided complete and accurate information.
Pfizer Canada is committed to an open dialogue with the Canadian health care community. We welcome criticism as an opportunity to improve the quality of our services. We therefore would like to understand why our response to Lexchin did not meet his expectations.
Bernard M. Prigent Vice President and Medical Director Pfizer Canada Inc. Kirkland, Que.
Reference
- 1.Lexchin J. Inaccessibility of drug reports [letter]. CMAJ 2002;166(10):1251. [PMC free article] [PubMed]